Efficacy of SEROQUEL in selective serotonin reuptake inhibitors (SSRI)-resistant major depressive disorder - UNIQUE
Study identifier:D1449C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant major depressive disorder.
Medical condition
Major depressive disorder
Phase
Phase 2
Healthy volunteers
No
Study drug
Quetiapine fumarate (Seroquel)
Sex
All
Actual Enrollment
-
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Mar 2006
Primary Completion Date: 01 Nov 2007
Study Completion Date: 01 Nov 2007
Study design
Allocation: N/A
Endpoint Classification: None
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Pr. Demyttenaere
KUL
